Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment
Background: Several trials show that tumor markers at primary diagnosis of cancer have prognostic relevance and can predict dissemination of the disease. While MUC-1 markers are frequently used to monitor treatment efficacy in metastatic breast cancer, their role at primary diagnosis or during follo...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 30, 2010
|
| In: |
Anticancer research
Year: 2010, Volume: 30, Issue: 5, Pages: 1837-1841 |
| ISSN: | 1791-7530 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://ar.iiarjournals.org/content/30/5/1837
|
| Author Notes: | Brigitte Rack, Christian Schindlbeck, Julia Jückstock, Eva-Maria Genss, Philip Hepp, Ralf Lorenz, Hans Tesch, Andreas Schneeweiss, Matthias W. Beckmann, Werner Lichtenegger, Harald Sommer, Klaus Friese and Wolfgang Janni, for the SUCCESS Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1844873803 | ||
| 003 | DE-627 | ||
| 005 | 20230710135143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230509s2010 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1844873803 | ||
| 035 | |a (DE-599)KXP1844873803 | ||
| 035 | |a (OCoLC)1389805661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rack, Brigitte K. |d 1975- |e VerfasserIn |0 (DE-588)128780479 |0 (DE-627)379681420 |0 (DE-576)297329340 |4 aut | |
| 245 | 1 | 0 | |a Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment |c Brigitte Rack, Christian Schindlbeck, Julia Jückstock, Eva-Maria Genss, Philip Hepp, Ralf Lorenz, Hans Tesch, Andreas Schneeweiss, Matthias W. Beckmann, Werner Lichtenegger, Harald Sommer, Klaus Friese and Wolfgang Janni, for the SUCCESS Study Group |
| 264 | 1 | |c June 30, 2010 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.05.2023 | ||
| 520 | |a Background: Several trials show that tumor markers at primary diagnosis of cancer have prognostic relevance and can predict dissemination of the disease. While MUC-1 markers are frequently used to monitor treatment efficacy in metastatic breast cancer, their role at primary diagnosis or during follow-up remains unclear. This translational research project within the SUCCESS trial evaluates the role of the tumor marker CA 27.29 before and after adjuvant chemotherapy, as well as after two and then five years in patients with early breast cancer. Patients and Methods: The SUCCESS trial compared FEC (500/100/500)-docetaxel (100) vs. FEC (500/100/500)-docetaxel/gemcitabine (75/2000) and two vs. five years of zoledronate treatment in node-positive and high-risk node-negative patients with primary breast cancer. CA 27.29 was measured before chemotherapy in 2669 patients with the reagent ST AIA-PACK CA 27.29 for AIA-600II-Analyzer (Tosoh Bioscience, Belgium). Results of CA 27.29 above 31 U/ml were regarded as positive. Results: 7.6% of patients had elevated marker levels after the completion of primary surgical treatment but before initiation of chemotherapy (n=202, mean 19, range 3-410 U/ml). No correlation between nodal status (p=0.55), grading (p=0.85), hormonal status (p=0.21), HER2/neu status on the primary tumor (p=0.58) and CA 27.29 was shown. However, larger tumor size (p=0.02), lobular histology (p<0.0001), older age (p<0.001) and postmenopausal hormone status before the start of treatment (p=0.006) were significantly associated with higher CA 27.29 levels. Conclusion: These data indicate a close relationship between CA 27.29 and tumor mass persisting even several weeks after surgery, but also identify potential confounding factors that should be considered in interpreting tumor marker results. Further follow-up of the SUCCESS trial will clarify whether CA 27.29 measured after surgery but before the start of systemic treatment is prognostically relevant and whether it is a useful marker for treatment monitoring in the adjuvant setting. | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a CA 27.29 | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a MUC-1 | |
| 650 | 4 | |a tumor marker | |
| 700 | 1 | |a Schindlbeck, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jückstock, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Genss, Eva-Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hepp, Philip |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lorenz, Ralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tesch, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Beckmann, Matthias W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lichtenegger, Werner |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sommer, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Friese, Klaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janni, Wolfgang |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004 |g 30(2010), 5 vom: Juni, Seite 1837-1841 |h Online-Ressource |w (DE-627)387478493 |w (DE-600)2145376-7 |w (DE-576)358408717 |x 1791-7530 |7 nnas |a Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment |
| 773 | 1 | 8 | |g volume:30 |g year:2010 |g number:5 |g month:06 |g pages:1837-1841 |g extent:5 |a Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment |
| 856 | 4 | 0 | |u https://ar.iiarjournals.org/content/30/5/1837 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230509 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1844873803 |e 4320006941 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Rack, Brigitte K.","given":"Brigitte K.","family":"Rack","role":"aut"},{"role":"aut","family":"Schindlbeck","given":"Christian","display":"Schindlbeck, Christian"},{"display":"Jückstock, Julia","given":"Julia","role":"aut","family":"Jückstock"},{"role":"aut","family":"Genss","given":"Eva-Maria","display":"Genss, Eva-Maria"},{"family":"Hepp","role":"aut","given":"Philip","display":"Hepp, Philip"},{"family":"Lorenz","role":"aut","given":"Ralf","display":"Lorenz, Ralf"},{"family":"Tesch","role":"aut","display":"Tesch, Hans","given":"Hans"},{"role":"aut","family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas"},{"given":"Matthias W.","display":"Beckmann, Matthias W.","role":"aut","family":"Beckmann"},{"role":"aut","family":"Lichtenegger","display":"Lichtenegger, Werner","given":"Werner"},{"display":"Sommer, Harald","given":"Harald","role":"aut","family":"Sommer"},{"display":"Friese, Klaus","given":"Klaus","family":"Friese","role":"aut"},{"family":"Janni","role":"aut","given":"Wolfgang","display":"Janni, Wolfgang"}],"recId":"1844873803","note":["Gesehen am 09.05.2023"],"language":["eng"],"name":{"displayForm":["Brigitte Rack, Christian Schindlbeck, Julia Jückstock, Eva-Maria Genss, Philip Hepp, Ralf Lorenz, Hans Tesch, Andreas Schneeweiss, Matthias W. Beckmann, Werner Lichtenegger, Harald Sommer, Klaus Friese and Wolfgang Janni, for the SUCCESS Study Group"]},"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatmentAnticancer research","language":["eng"],"part":{"volume":"30","year":"2010","text":"30(2010), 5 vom: Juni, Seite 1837-1841","issue":"5","extent":"5","pages":"1837-1841"},"note":["Gesehen am 26.02.13"],"pubHistory":["Nachgewiesen 24.2004 -"],"title":[{"title_sort":"Anticancer research","title":"Anticancer research","subtitle":"international journal of cancer research and treatment"}],"id":{"zdb":["2145376-7"],"eki":["387478493"],"issn":["1791-7530"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"International Institute of Anticancer Research","dateIssuedDisp":"2004-","dateIssuedKey":"2004","publisherPlace":"Kapandriti, Attiki, Greece"}],"name":{"displayForm":["International Institute of Anticancer Research"]},"recId":"387478493"}],"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"June 30, 2010"}],"title":[{"title_sort":"Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment","title":"Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1844873803"]},"physDesc":[{"extent":"5 S."}]} | ||
| SRT | |a RACKBRIGITPREVALENCE3020 | ||